SARS-CoV-2 is the etiological agent of the coronavirus disease-19 (COVID-19) and is
responsible for the pandemic that started in 2020. The virus enters the host cell through the …

Updated immunization strategies are needed to address multiple severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants. Here we report interim results from an …

Immunogenicity of SARS-CoV-2 vaccination is diminished in hematopoietic stem cell
transplant (HSCT) recipients. To summarize current evidence and identify risk factors for …

Background The reactogenicity and immunogenicity of coronavirus disease 2019 (COVID-
19) vaccines are well studied. Little is known regarding the relationship between …

This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety,
reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 …

Background Solid organ transplant recipients (SOTRs) are at high risk for severe COVID-19.
Methods This open-label, phase 3b trial evaluated mRNA-1273 in 137 kidney and 77 liver …

Abstract 1 Background: The reactogenicity and immunogenicity of Coronavirus 2019
(COVID-19) 2 vaccines is well-studied. Little is known regarding the relationship between …

To overcome the COVID-19 pandemic, the development of safe and effective vaccines is
crucial. With the enormous information available on vaccine development for COVID-19 …

Vaccination with two injections of mRNA-1273 (100-μg) was shown to be safe and e cacious
at preventing coronavirus disease 2019 (COVID-19) in the Coronavirus E cacy (COVE) trial …

Le informazioni attualmente disponibili in letteratura circa la sicurezza e l'efficacia del
Molnupiravir nella pratica clinica di tutti i giorni sono davvero scarse. L'obbiettivo di questa …